Practitioner's Corner with Dr Seth Bilazarian

 
 
  • Hypertension Guidelines: Clear as Mud Dr. Bilazarian gives his take on JNC 8 and the implications for the practicing physician when professional societies disagree on guidelines.
  • Keeping Positive About Negative Trials   The first 4 latebreakers from AHA were 'negative' trials, leaving Dr. Bilazarian disappointed, but upon reflection, he is optimistic about cardiovascular medicine and the merits of medical meetings.
  • Guidelines Update 'ATP-4' -- Finally!   Dr. Bilazarian gives his topline take on the new cholesterol, CV risk, and obesity guidelines.
  • Managing Novel Oral Anticoagulant Transitions   To bridge or not to bridge? Dr. Seth Bilazarian examines the data on transitioning patients on and off novel oral anticoagulants and charts the path forward.
  • Cardioversion Turns 50: What's Changed?   Cardioversion first saw the light of day in 1963, and to celebrate its birthday, Dr. Seth Bilazarian turns his attention to the procedure, its usage, and the path it's taken over the half century.
  • How Is Your 96-Year-Old Patient Doing Post-TAVI?   Dr. Seth Bilazarian shares his thoughts on 'aggressive' treatment in the very elderly, why age should no longer be considered a standalone criterion, and the many implications of extreme longevity.
  • Cardiologists Are Ageists   It's the peg on which we hang our clinical cases and somewhat of a sliding scale. When today's 80 is yesterday's 65, how does age affect the care we give our patients? Dr. Seth Bilazarian explores.
  • Renal denervation: Reviewing the latest data   Dr Seth Bilazarian did the rounds of the renal-denervation sessions at ACC 2013 and shares his findings—from Symplicity HTN-2 data, pathological reports on the actual location of the nerves in the renal artery, to a review of devices—and his hopes...
  • Adopting novel antiplatelet therapies: What's holding you back?   In his presentation at ACC 2013, Dr Bob Harrington argued that it can take practitioners 30 years to adopt new therapeutic regimens. What's holding us back? Ignorance? Habit? Cost? Ineffective interaction with industry in the clinical setting?
  • Finding our way in appropriate-use criteria   The initial push-back against AUC seems to have given way to a certain acceptance of "our lot" as shown by a series of presentations (one even humorous!) during ACC 2013.
  • Goodbye CV practice memorabilia, hello ACO perfection!   Office renovations give a chance to pause and reminisce about the practice of yesteryear as Dr Seth Bilazarian empties his office drawers of promo knickknacks, dictation audio tapes, prescription pads, and mangy old stethoscopes.
  • Clopidogrel pretreatment: Reading between the (head) lines   Research by Gilles Montalescot's group on the association of clopidogrel pretreatment with mortality, CV events, and major bleeding in PCI, is an excellent addition to our knowledge base and—depending on which headline you believe—there's something in it
  • Chest compressions: Radical change to practice?   It's supposed to be a foregone conclusion (right?), but one debate at AHA 2012 provided convincing arguments against chest compressions. This could be a major paradigm shift: To compress or not to compress?
  • Forget about fish oil and multivitamins for secondary prevention of CV events   There seems to be hope on the horizon for secondary prevention—as shown by promising results with colchicine and PCSK9 here in Los Angeles—but it's time to ditch your fish oil and multivitamins.
  • Frustrated in Los Angeles: Platelet function testing isn't working out   From a clinical perspective, it's disappointing that the results of the ARCTIC and TRILOGY angiography substudy do not shine a favorable light on platelet function testing. What's best for our patients?
  • Pradaxa turns 19 (in dog years)   As Pradaxa (dabigatran) celebrates its second anniversary since FDA approval, the clock is ticking to 2018, when its first patent is set to expire.
  • What to do about hospital readmission rates   As the CMS moves to cut reimbursement based on high rates of hospital readmission for MI, heart failure, and pneumonia, how can cardiologists—working with other healthcare providers, patients, and their families—provide optimum care and keep people out...
  • Physician, are you burning out?   Forty-six percent of physician respondents to a recent survey admitted to one of the aspects of burnout, as defined by emotional exhaustion, depersonalization, or a feeling of low personal accomplishment.
  • Keeping up with journals   Staying on top of the constant inflow of journals is a daunting task. How do you go about it?
  • Happy 25th birthday, lovastatin (Mevacor)! What next?   As we mark an important birthday of the first statin (lovastatin), it's good to celebrate the success of this class of drugs and ponder what the next big thing in prevention of cardiovascular disease will be.